Mary Canning

Mary Canning is a Principal with Epidarex Capital, a transatlantic venture fund focused on building highly innovative early-stage life science companies in the UK and US. Mary leads due diligence for Epidarex investments and holds board positions with portfolio companies LUNAC Therapeutics and Caldan Therapeutics. She also serves as an independent director with GU Holdings Ltd, the University of Glasgow's investment company for spin-out activity. Prior to joining Epidarex, she led commercialisation of IP from several MRC research institutes. She has a PhD from the University of Edinburgh.